Market Research Report
Chemotherapy-induced thrombocytopenia (CIT) - Market Insights, Epidemiology, and Market Forecast - 2028
|Published by||DelveInsight Business Research LLP||Product code||915409|
|Published||Content info||128 Pages
Delivery time: 1-2 business days
|Chemotherapy-induced thrombocytopenia (CIT) - Market Insights, Epidemiology, and Market Forecast - 2028|
|Published: November 1, 2019||Content info: 128 Pages||
DelveInsight's 'Chemotherapy-induced thrombocytopenia (CIT)-Market Insights, Epidemiology, and Market Forecast-2028' report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Chemotherapy-induced thrombocytopenia in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Chemotherapy-induced thrombocytopenia from 2017 to 2028 segmented by seven major markets.
Thrombocytopenia can be defined as the deficiency of platelets (thrombocytes) that increase the risk of bleeding. Platelets maintain vascular endothelium integrity and control hemorrhage control following small-vessel injury by platelet plug formation and provide a firm, stable, fibrin clot in large injury.
The National Cancer Institute Common Toxicity Criteria defines Chemotherapy-induced thrombocytopenia (CIT) as a platelet count of fewer than 75,000 cells/µL, with the risk of bleeding, complications increase with lower platelet counts. However, there is no standard definition of CIT, it depends mostly on the observed platelet count reduction in clinical settings. It is a frequent complication associated with cancer therapy and the decrease in platelet count persists despite adequate recovery time from prior chemotherapy nadir, in the context of recovery of white cells and red cells.
Study Period: 2017-2028
Chemotherapy-induced thrombocytopenia - Disease Understanding and Diagnosis
CIT is a common hematologic toxicity of myelosuppressive (side effects of some cancer treatments) and ablative therapies (used to destroy abnormal tissues). It is treated on the basis of etiology, severity, and duration of thrombocytopenia. Thrombocytopenia is classified as Idiopathic Thrombocytopenic Purpura, Thrombotic Thrombocytopenic Purpura, Drug-Induced Thrombocytopenia, and others based on etiology.
Diagnosis of thrombocytopenia must be based on medical history, physical exam and the test result of an individual. For the analysis of medical history, the knowledge about the medicines and given treatment with chemo-regimens and general observation of the person, while taking chemotherapy are required. Along with this, the knowledge about the NCI grade adverse events associated with chemo-regimens may be helpful for early identification of CIT and other hematological toxicity.
The Chemotherapy-induced thrombocytopenia epidemiology division provides insights about historical and current incident pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL).
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incident cases of CIT and Total Incidence of CIT by Chemotherapeutic Agents) scenario of Chemotherapy-induced thrombocytopenia in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017 to 2028.
According to DelveInsight, the total Incident cases of Chemotherapy-induced thrombocytopenia (CIT) in the 7MM was found to be 302,735 in 2017. The incidence of Chemotherapy-induced thrombocytopenia in the 7MM is expected to increase during the study period of 2017-2028.
This segment of the Chemotherapy-induced thrombocytopenia report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Currently, the management of chemotherapy-associated thrombocytopenia often involves treating any other underlying cause of thrombocytopenia by avoiding antibiotics, treating infection, and controlling coagulopathy. The treatment of CIT comprises of dose reductions or treatment delays of chemotherapy, platelet transfusions as a standard treatment choice. Recombinant interleukin-11 (IL-11) (Oprelvekin) is the only available option in pharmacological management. Antifibrinolytic agents, such as epsilon-aminocaproic acid or tranexamic acid are used as off-label.
Detailed chapters of current therapy i.e. Neumega (Wyeth Pharmaceutical) and emerging therapies, such as Avatrombopag (Dova Pharmaceuticals), Romiplostim (Amgen), Eltrombopag (Novartis), and others have also been provided in the report.
The Chemotherapy-induced thrombocytopenia market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
According to DelveInsight, the market for Chemotherapy-induced thrombocytopenia in 7MM was found to be approximately USD 921.81 Million in 2017.
Chemotherapy-induced thrombocytopenia market size in the United States accounted for 47% of the total market in 2017. The US-led the market in 2017, followed by the EU5 and Japan, respectively. Due to the high incidence of this disease in the region, the Chemotherapy-induced thrombocytopenia treatment market in the US is expected to dominate the market during the forecast period (2019-2028).
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies, and sales of each drug.
The dynamics of Chemotherapy-induced thrombocytopenia market is anticipated to change in the coming years owing to the expected launch of emerging therapies, such as Avatrombopag (Dova Pharmaceuticals), Romiplostim (Amgen), Eltrombopag (Novartis), and others in the Chemotherapy-induced thrombocytopenia market by 2028.